BG Medicine
True Health Declines to Assume BG Medicine Galectin-3 Supply Agreement
The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.
BG Medicine to Delist Stock; Posts 44 Percent Drop in 2015 Revenues
The company, which counts fewer than 300 holders of its common stock, said that it was delisting due to the resources required to remain a public company.
BG Medicine's Shares Plummet After Firm Withdraws Filing for Expanded Use of Galectin-3 Test
BG aimed to use the test to assess risk of fatal cardiovascular events in older adults with no history of cardiovascular, cerebrovascular, or vascular disease.
BG Medicine Amends Galectin-3 Test Sales Agreement With Abbott
The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.
Nasdaq to Delist BG Medicine’s Stock
The company was unable to comply with requirements including having a minimum bid price of at least $1 per share and stockholder equity of at least $2.5 million.